cRGDfK

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cRGDfK
• 英文别名: c(RGDfK)；2-[8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
• 化学式: C₂₇H₄₁N₉O₇
• 分子量: 603.679
• InChiKey: NVHPXYIRNJFKTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  273
• 氢给体数：
  9
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  cRGDfK 在 copper(II) sulfate 、 sodium ascorbate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 23.0h， 生成
  参考文献：
  名称：

  Synthesis and comparativein vivoevaluation of^99mTc(CO)₃-labeled PEGylated and non-PEGylated cRGDfK peptide monomers

  摘要：

  This work aimed at studying the effect of insertion of medium PEG (PEG7) on the pharmacokinetic behavior of cRGDfK peptide in comparison with the non‐PEGylated analogue. The cRGDfK peptide has thus been derivatized at ε‐amino group of lysine by conjugation with N3–PEG7–COOH/N3–CH2–COOH to prepare a PEGylated and a non‐PEGylated analogue of cRGDfK. A tridentate chelator was then incorporated by click chemistry conjugation of the two peptide azides for radiolabeling with [99mTc(CO)3(H2O)3]+ precursor. Comparative in vivo evaluation of the two 99mTc(CO)3‐labeled radiotracers, 99mTc(CO)3–Pra–Tz–CH2–cRGDfK 5 and 99mTc(CO)3–Pra–Tz–PEG7–cRGDfK 6, was carried out in C57BL/6 mice bearing αvβ3‐positive melanoma tumors to determine their potential toward targeting integrin αvβ3 receptors. The radiotracers exhibited excellent stability in saline as well as in serum. Maximum tumor uptake for the two radiotracers was observed at 30 min p.i. (5: 3.0 ± 0.7% ID/g; 6: 4.1 ± 0.5% ID/g). The two neutral 99mTc(CO)3 radiotracers prepared exhibited receptor‐mediated uptake in melanoma tumor. The increase in the tumor uptake on introduction of PEG7 unit was accompanied by slower clearance from other organs which resulted in decreased target‐to‐background ratios. The in vivo kinetics of 99mTc(CO)3‐labeled radiotracer, 99mTc(CO)3–Pra–Tz–CH2–cRGDfK 5 with only methylene unit as the spacer, was found to be more favorable due to higher tumor/blood, tumor/liver, tumor/kidney, and tumor/lung ratios.

  DOI：

  10.1111/cbdd.12844
• 作为产物：
  描述：

  c[R]GDfK 生成 cRGDfK
  参考文献：
  名称：

  [EN] TRIPLET-TRIPLET ANNIHILATION-BASED UPCONVERSION
  [FR] CONVERSION ASCENDANTE PAR ANNIHILATION TRIPLET-TRIPLET

  摘要：

  本发明通常涉及各种光反应，包括基于三重态-三重态湮灭上转换的反应。本发明的一个方面涉及吸收能量（例如来自光子）的系统和方法，将该能量通过三重态-三重态能量转移转移到湮灭体，通过上转换产生更高的能量状态，然后将该能量转移以裂解可裂解或其他活性基团，例如为了释放可释放基团。能量可以通过Forster共振能量转移传递到基团。在某些情况下，这些可以包含在适当的载体材料中，例如颗粒或微胶囊中。这些系统和方法可以用于各种应用，包括各种生物学或物理学应用。例如，这些系统和方法可以用于将药物或其他可释放基团传递到身体的受光过度影响的区域，例如眼睛。本发明的其他方面通常涉及制备或使用这些系统的方法，包括包括这些系统的试剂盒等。

  公开号：

  WO2017004310A1

文献信息

• 双光子吸收钌配合物的制备方法及其作为肿 瘤探针的应用
  申请人：暨南大学

  公开号：CN108373487B

  公开（公告）日：2020-04-14

  本发明公开了一种双光子吸收钌配合物的制备方法及其作为肿瘤探针的应用。该双光子吸收钌配合物为Ru‑1和Ru‑RGD中的至少一种；其中，Ru‑1和Ru‑RGD的阳离子的结构式如式I和式II所示。本发明的双光子吸收钌配合物利用微波辐射的方法合成，将具有取代基团的配合物通过连接具有靶向性RGD多肽的分子，合成肿瘤靶向性钌配合物。本发明中高效地合成了钌配合物，减少了有机溶剂的消耗量和合成时间；所合成的钌配合物具有良好的单、双光子细胞成像能力以及靶向宫颈癌细胞的功能，能够同时实现对肿瘤的诊断和治疗，具有极大临床应用潜力。
• POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS
  申请人：Lee Young B.

  公开号：US20110086111A1

  公开（公告）日：2011-04-14

  The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.

  该发明涉及用于治疗温血动物体内癌组织的组合物，其中包含附着在聚合物载体上的一种或两种抗癌药物，所述聚合物载体具有源自N-(2-羧基丙基)甲基丙烯酰胺(2-CPMA)、N-(3-羧基丙基)甲基丙烯酰胺(3-CPMA)、N-(2-氨基丙基)甲基丙烯酰胺(2-APMA)和/或N-(3-氨基丙基)甲基丙烯酰胺(3-APMA)中的一个或多个单体单元。组合物中的抗癌药物可以通过在细胞内易受溶酶体酶水解的侧链附着在所述聚合物载体上。组合物还可以包括附着在聚合物载体上的靶向配体，可选地通过第二连接剂连接。
• HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE
  申请人：Lee Young B.

  公开号：US20100099644A1

  公开（公告）日：2010-04-22

  Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.
• p-BORONOPHENYLALANINE DERIVATIVE AND COMPOSITION CONTAINING SAME, AND KIT FOR PRODUCING SAID DERIVATIVE AND COMPOSITION
  申请人：TOKYO INSTITUTE OF TECHNOLOGY

  公开号：US20210040244A1

  公开（公告）日：2021-02-11

  The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.